1. |
Higher risk of TB after long visits to highly endemic nations |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
How should TNF inhibitors be used in rheumatoid arthritis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 3-3
Carmen Innes,
Preview
|
|
摘要:
Tumour necrosis factor (TNF) inhibitors are promising new agents for the treatment of rheumatoid arthritis. Yet the optimal use of these agents has not yet been determined, leading experts in the rheumatology field to develop consensus statements on the best use of TNF inhibitors. At the Annual European Congress of Rheumatology [Nice, France; June 2000], Professor Josef Smolen from the University of Vienna, Austria, gave delegates a review and update of these statements.*
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
HRT is underutilised in US low-income elderly |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
HAART breaking news: structured intermittent therapy brings hope |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 7-7
Carmen Innes,
Preview
|
|
摘要:
One of the hottest topics at the 13th International AIDS Conference [Durban, South Africa; July 2000] was that of interrupted therapy for patients with HIV infection. Researchers say that the aim of interrupted therapy is to limit time spent on highly active antiretroviral therapy (HAART), thereby improving compliance and reducing adverse effects and costs of treatment. At a plenary session, Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, US, discussed the results of 2 encouraging studies of structured intermittent therapy (SIT), but also warned delegates that such therapy is still in its infancy.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
Cariporide: meeting the cell protection challenge in MI? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Hard data on 'Viagra' for diabetics with erectile dysfunction |
|
Inpharma Weekly,
Volume &NA;,
Issue 1250,
2000,
Page 11-12
Charles Bankhead,
Preview
|
|
摘要:
Sildenafil ['Viagra'] has proven effective in the treatment of erectile dysfunction associated with diabetes mellitus. However, few investigations have evaluated the relative efficacy of sildenafil in patients with type 1, compared with type 2, diabetes. Data reported at the 60th Scientific Sessions of the American Diabetes Association [San Antonio, US; June 2000] suggest that sildenafil works equally well in patients who have type 1 or type 2 diabetes. Other investigators showed that the incidence of adverse events in patients receiving sildenafil is low and is comparable between men with and without diabetes mellitus. A study purported to be the first clinical study limited to patients with type 2 diabetes provided more evidence of sildenafil's efficacy in the treatment of erectile dysfunction associated with diabetes mellitus. A comparison of sildenafil and intracavernosal alprostadil showed similar efficacy between the 2 treatments, but alprostadil was associated with substantially more adverse events, which the investigators considered treatment-limiting.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|